NR4A1 and breast cancer: The current clinical/routine using the classification of BC subtypes involves a semi-quantitative immunohistochemistry (IHC)-based analysis of hormone receptors, as well as other surface antigens, which cannot optimally address BC heterogeneity and drug resistance [301].